Opioid Peptide Drug Development: Transport of Opioid Chimeric Peptides Through the Blood-Brain Barrier

1992 ◽  
Author(s):  
William M. Pardridge ◽  
Keyword(s):  
Drug Development ◽  
Blood Brain Barrier ◽  
Opioid Peptide ◽  
Brain Barrier ◽  
Peptide Drug ◽  
Blood Brain ◽  
Chimeric Peptides

Blood-brain barrier transport of a novel µ1-specific opioid peptide, H-Tyr-d-Arg-Phe-β-Ala-OH (TAPA)

2003 ◽  
Vol 84 (5) ◽  
pp. 1154-1161 ◽  
Author(s):  
Yoshiharu Deguchi ◽  
Yusaku Miyakawa ◽  
Shinobu Sakurada ◽  
Yu Naito ◽  
Kazuhiro Morimoto ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Opioid Peptide ◽  
Brain Barrier ◽  
Blood Brain

scholarly journals Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

2020 ◽  
Vol 13 (11) ◽  
pp. 394 ◽  
Author(s):  
William M. Pardridge
Keyword(s):  
Alzheimer’S Disease ◽  
Drug Delivery ◽  
Alzheimer's Disease ◽  
Drug Development ◽  
Blood Brain Barrier ◽  
New Drugs ◽  
Brain Barrier ◽  
Biologic Drugs ◽  
Blood Brain ◽  
Delivery Technology

Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of small molecule drugs do not cross the BBB, and ~100% of biologic drugs do not cross the BBB, so BBB drug delivery technology is needed in AD drug development. Second, the pharmaceutical industry has not developed BBB drug delivery technology, which would enable industry to invent new therapeutics for AD that actually penetrate into brain parenchyma from blood. In 2020, less than 1% of all AD drug development projects use a BBB drug delivery technology. The pathogenesis of AD involves chronic neuro-inflammation, the progressive deposition of insoluble amyloid-beta or tau aggregates, and neural degeneration. New drugs that both attack these multiple sites in AD, and that have been coupled with BBB drug delivery technology, can lead to new and effective treatments of this serious disorder.

A comparison of the effects of p-glycoprotein inhibitors on the blood–brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE)

2009 ◽  
Vol 98 (6) ◽  
pp. 2227-2236 ◽  
Author(s):  
Hui Ouyang ◽  
Thomas E. Andersen ◽  
Weiqing Chen ◽  
Rebecca Nofsinger ◽  
Bente Steffansen ◽  
...  
Keyword(s):  
Blood Brain Barrier ◽  
Opioid Peptide ◽  
Brain Barrier ◽  
P Glycoprotein ◽  
Blood Brain ◽  
Cyclic Prodrugs ◽  
Glycoprotein Inhibitors

scholarly journals Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma

Oncotarget ◽  
2016 ◽  
Vol 7 (48) ◽  
pp. 79401-79407 ◽  
Author(s):  
Ying Li ◽  
Xuemin Zheng ◽  
Min Gong ◽  
Jianning Zhang
Keyword(s):  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Peptide Drug ◽  
Drug Conjugate ◽  
Blood Brain

scholarly journals The blood-brain barrier: Bottleneck in brain drug development

NeuroRx ◽  
2005 ◽  
Vol 2 (1) ◽  
pp. 3-14 ◽  
Author(s):  
William M. Pardridge
Keyword(s):  
Drug Development ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Blood Brain
Sign in / Sign up

Export Citation Format

Share Document